摘要
儿童哮喘大多是过敏性哮喘,特异性免疫治疗是目前惟一针对过敏性疾病的对因治疗,和对症治疗相辅相成,最终达到治愈过敏性疾病的目的。舌下特异性免疫治疗(SLIT)是近年来提倡的针对过敏性哮喘的新疗法。SLIT确切的作用机制仍不清楚,国内外研究证实SLIT对儿童哮喘安全有效,无严重不良事件发生,依从性较好,能预防新的过敏症发生。SLIT可能提供机制填补目前过敏症实验的空白。
Childhood asthma is allergic asthma mostly,specific immunotherapy is the only etiological treatment aiming at allergic diseases,to complement symptomatic treatment each other,ultimately achieve the cure of allergic diseases.Sublingual immunotherapy was promoted to treat allergic asthma for the past few years.The precise mechanisms of SLIT remain unclear,SLIT have been confirmed both clinical efficacy and safety at home and abroad.No severe adverse events happened.Adherence is better,SLIT have the ability to prevent new allergy.SLIT may provide a mechanism to ＂fill the gap＂ in current allergy practice.
出处
《医学综述》
2010年第8期1229-1231,共3页
Medical Recapitulate
